Company intelligence / Profile preview

AccuBreak Diagnostics

Hollywood, Florida, United States

Ownership: Private
Employees: ~24
Development stage: Other

Overview

Accu-Break Pharmaceuticals has developed a patented bi-layer tablet technology that allows for precise and accurate splitting into halves, thirds, or quarters, enabling flexible dosing for pediatric, geriatric, or veterinary use. This technology, featuring a pharmacologically inert breaking region, enhances patient compliance, reduces dosing errors, and extends product life cycles for pharmaceutical manufacturers. The company operates as a technology licensing and product development platform, with its technology already commercialized in Japan.

Industry: Non-Drug Biotech

Partnerships

CMIC CMO (Japan) – exclusive agent and manufacturing partner for Accu-Break tablet technology in Japan[11]

Beyond the preview

Go deeper on AccuBreak Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AccuBreak Diagnostics.

Explore the full profile